Windtree Therapeutics announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel from its offices in Taipei, Taiwan will participate in the collaboration. The scientific collaboration includes the Company’s lead product candidate istaroxime and the next generation compounds called SERCA2a activators. “We are pleased to utilize this scientific collaboration to further support the characterization of the potential benefits of SERCA2a activation in cardiovascular disease and support the advancement of the next generation assets in our portfolio,” said Craig Fraser, Windtree’s President and Chief Executive Officer. “This collaboration recently provided preclinical data showing reduction in ischemia-reperfusion induced arrythmias with istaroxime and a pure SERCA2a activator compound.” Outside of this scientific collaboration, istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock. Study results are expected in mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on WINT:
- Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
- Windtree Therapeutics Seeks Strategic Alternatives with Ladenburg Thalmann
- Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
- Windtree Therapeutics engages Ladenburg to evaluate strategic alternatives
- Windtree Therapeutics Announces Equity Sales Filing Update